Eyepoint Pharmaceuticals, Inc.
Clinical trials sponsored by Eyepoint Pharmaceuticals, Inc., explained in plain language.
-
New eye implant could slash injections for diabetes-related vision loss
Disease control Recruiting nowThis study tests an eye implant called EYP-1901 that slowly releases medication to treat diabetic macular edema, a condition that causes vision loss in people with diabetes. About 240 adults with this eye condition will receive either the implant or standard aflibercept injection…
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New eye drug could cut injection frequency for diabetic vision loss
Disease control Recruiting nowThis phase 3 study tests whether a new drug, EYP-1901, works as well as the standard treatment aflibercept for diabetic macular edema, a condition that causes vision loss. About 240 adults with DME will receive either EYP-1901 or aflibercept injections. The goal is to see if EYP-…
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC